title: Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: impact of graft-versus-myeloma effect.
abstract: A total of 228 patients with multiple myeloma (MM), 166 patients receiving autologous transplantation (124 PBSC and 38 BM) and 66 patients receiving T-cell-depleted allogeneic transplantation were analyzed to compare overall survival (OS), progression-free survival (PFS) and risk of relapse. Patients receiving autologous transplantation had a significantly improved OS (P=0.006) and PFS (P=0.002) at 2 years with OS and PFS for autologous transplant 74% and 48%, respectively, compared with 51% and 28% for allogeneic transplantation. By 4 years after transplantation, outcome was similar with OS and PFS for autologous transplantation 41% and 23%, respectively, compared with 39% and 18% for allogeneic transplantation. The 4-year cumulative incidence of nonrelapse mortality was significantly higher in patients receiving allogeneic transplantation (24% vs 13%) (P=0.004). Relapse was the principle cause of treatment failure for both groups; however, there was a significantly reduced risk of relapse associated with allogeneic transplantation at 4 years: 46% for allograft vs 56% for autograft (P=0.02). Despite a lower risk of relapse after allogeneic transplantation, autologous transplantation is associated with improved OS and PFS compared with allogeneic transplantation in patients with MM. Strategies focused on reducing nonrelapse mortality in allogeneic transplantation may translate into an improved outcome for patients receiving allogeneic transplantation.
authors.affiliation: Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, MA 02215, USA. Edwin_alyea@DFCI.Harvard.edu
authors.forename: E
authors.initials: E
authors.lastname: Alyea
authors.forename: E
authors.initials: E
authors.lastname: Weller
authors.forename: R
authors.initials: R
authors.lastname: Schlossman
authors.forename: C
authors.initials: C
authors.lastname: Canning
authors.forename: P
authors.initials: P
authors.lastname: Mauch
authors.forename: A
authors.initials: A
authors.lastname: Ng
authors.forename: D
authors.initials: D
authors.lastname: Fisher
authors.forename: J
authors.initials: J
authors.lastname: Gribben
authors.forename: A
authors.initials: A
authors.lastname: Freeman
authors.forename: B
authors.initials: B
authors.lastname: Parikh
authors.forename: P
authors.initials: P
authors.lastname: Richardson
authors.forename: R
authors.initials: R
authors.lastname: Soiffer
authors.forename: J
authors.initials: J
authors.lastname: Ritz
authors.forename: K C
authors.initials: KC
authors.lastname: Anderson
mesh_terms: D000328:Adult; D000368:Aged; D018572:Disease-Free Survival; D005260:Female; D006086:Graft vs Host Disease / Q000517:prevention & control; D020350:Graft vs Tumor Effect; D006801:Humans; D015993:Life Tables; D008212:Lymphocyte Depletion; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000401:mortality / Q000628:therapy*; D036102:Peripheral Blood Stem Cell Transplantation / Q000379:methods* / Q000401:mortality / Q000706:statistics & numerical data; D016016:Proportional Hazards Models; D012008:Recurrence; D012189:Retrospective Studies; D012306:Risk; D016019:Survival Analysis; D019172:Transplantation Conditioning; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous